Delays in Confirmatory Trials for Drug Applications Granted FDA’s Accelerated Approval Raise Concerns (OEI-01-21-00401) (2022)

Government Record · U.S. Department of Health and Human Services, Office of Inspector General · September 2022

U.S. Department of Health, 2022-09: OIG data snapshot on the 1992-2021 accelerated approval record: 278 applications, 104 with incomplete confirmatory trials, 35 of those (34%) past their original completion dates, and 35 of 278 (13%) withdrawn, 18 since January 2021.

More than one-third of accelerated approval drug applications with incomplete confirmatory trials are past their trials' original planned completion dates, including four that are more than 5 years past those dates.

p. 1

U.S. Department of Health, 2022-09: OIG data snapshot on the 1992-2021 accelerated approval record: 278 applications, 104 with incomplete confirmatory trials, 35 of those (34%) past their original completion dates, and 35 of 278 (13%) withdrawn, 18 since January 2021. PDF downloaded directly from oig.hhs.gov and text extracted locally. No funder or COI applicable (government audit). The report itself cites the Avastin case on p. 2 as an example of withdrawal delay: FDA announced intent in December 2010 and finalised withdrawal in November 2011. Companion OIG report OEI-01-21-00400 (2025) covers 3 of 24 drugs reviewed. Study type: regulatory record.